Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients

Diabetes, Obesity & Metabolism
D C ChanG F Watts

Abstract

Diabetic dyslipidaemia, characterized by hypertriglyceridaemia as a result of elevated serum very-low-density lipoprotein (VLDL) concentrations, contributes to the increased risk of cardiovascular disease (CVD) in type 2 diabetes (T2DM). Proprotein convertase subtilisin/kexin type 9 (PCSK9) may play a role in regulating VLDL metabolism. We investigated the effect of fenofibrate on serum PCSK9 and VLDL particle concentrations in T2DM patients already receiving statin therapy. In a double-blind randomized crossover study, 15 statin-treated T2DM patients (63 +/- 8 years, body mass index (BMI) 29 +/- 3 kg/m(2)) were treated with fenofibrate (145 mg/day) or matching placebo for 12 weeks. Serum PCSK9 concentrations were measured by immunoassay. VLDL particle concentration and size were determined by nuclear magnetic resonance spectroscopy. Fenofibrate decreased serum triglycerides (-23%), VLDL-triglycerides (-51%), total cholesterol (-11%), LDL-cholesterol (-16%), apolipoprotein B-100 (-16%), apolipoprotein C-III (-20%) and PCSK9 (-13%) concentrations compared with placebo (p < 0.05). Fenofibrate also decreased serum concentrations of large (-45%), medium (-66%) and small VLDL (-67%) particles (p < 0.05), without altering VLDL partic...Continue Reading

References

Jul 22, 1998·Arteriosclerosis, Thrombosis, and Vascular Biology·D S FreedmanJ A Walker
Nov 10, 1998·Circulation·B StaelsJ C Fruchart
May 6, 2003·Nature Genetics·Marianne AbifadelCatherine Boileau
Mar 24, 2006·The New England Journal of Medicine·Jonathan C CohenHelen H Hobbs
Nov 24, 2007·Journal of Lipid Research·Holly E CareskeyRobert J Konrad
Feb 5, 2008·The Journal of Biological Chemistry·Sanae KourimatePhilippe Costet
Mar 21, 2008·Journal of Lipid Research·Aldo GrefhorstJay D Horton
Jun 13, 2008·Lipids in Health and Disease·Janice MayneMichel Chrétien
Jun 21, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Dick C ChanP Hugh R Barrett
Jul 25, 2008·Atherosclerosis·Gilles LambertDerek E Piper
Aug 5, 2008·Biochemical and Biophysical Research Communications·LiXin ShanJoseph A Hedrick
Aug 13, 2008·Proceedings of the National Academy of Sciences of the United States of America·Maria Frank-KamenetskyKevin Fitzgerald
Nov 21, 2008·Journal of Lipid Research·Jay D HortonHelen H Hobbs
Dec 19, 2008·Diabetes Research and Clinical Practice·Allison M HodgeGraham G Giles
Mar 7, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Cédric Le MayPhilippe Costet
Apr 9, 2009·The Journal of Clinical Endocrinology and Metabolism·Susan G LakoskiHelen H Hobbs
May 16, 2009·Proceedings of the National Academy of Sciences of the United States of America·Joyce C Y ChanSimon M Jackson
Sep 10, 2009·Journal of Lipid Research·Jason S TrouttRobert J Konrad

❮ Previous
Next ❯

Citations

Sep 16, 2015·Clinical Pharmacology and Therapeutics·E Yang
Aug 8, 2015·American Journal of Respiratory and Critical Care Medicine·Keith R WalleyJohn H Boyd
Jul 19, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Yuan-Lin GuoJian-Jun Li
May 21, 2011·Atherosclerosis·Bertrand CariouPhilippe Costet
Nov 21, 2015·Journal of the American Heart Association·Karim Si-Tayeb, Bertrand Cariou
Sep 23, 2014·Stroke; a Journal of Cerebral Circulation·Jong-Ho ParkBruce Ovbiagele
Aug 15, 2017·Journal of Atherosclerosis and Thrombosis·Tsuyoshi Nozue
Apr 16, 2011·Current Opinion in Lipidology·Anne K Soutar
Jul 2, 2019·Annals of Clinical Biochemistry·Jonathan MaloSimon W Walker

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.